From DMPK Strategy to AI-Powered Antibody Design: Three Experts Share Precision Approaches to Break Through ADC Development Bottlenecks

Li Li, Vice President of iSPE BiopharmaceuticalsWith“DMPK Strategies for the Development of Next-Generation ADC Drugs”Titled “[Title],” the presentation first reviewed the common characteristics of targets, indications, antibodies, linkers, and payloads in marketed ADC drugs, pointing out that linker release efficiency in target tissues will be one of the core focuses in future ADC development. During payload screening, Li Li emphasized that payloads must be rapidly cleared from the body after detachment from the antibody; highlighted the need to pay close attention to drug–drug interactions; and noted key considerations such as exploring lysosome-stable toxins. Meanwhile, she shared several real-world case studies on ADC plasma stability and tissue distribution, providing a detailed explanation of methodological considerations in ADC bioanalysis. As a CRO supporting the development of innovative biologics, iSyBio currently offers access to more than 1,000 actionable targets across multiple therapeutic areas, including oncology and autoimmune diseases, providing comprehensive support for target screening and preclinical evaluation of ADCs and novel antibody-based therapeutics.

Duan Jianxin, Founder and Chairman of Aixin Dawei— Highlights the company’s proprietary technological approach"Selective Intracellular Activation" Molecular Delivery and Drug Development Technologies, capable of simultaneously addressing targeted drug delivery and overcoming clinical resistance. Leveraging the AKR1C3 enzyme-activated prodrug technology platform and the hypoxia-activated prodrug technology platform, multiple series of pipeline candidates have been developed. By integrating clinical exploratory data, he demonstrated the potential of AST-3424 and AST-001 in precise targeting, overcoming tumor chemotherapy/immunotherapy resistance, and safety profile, highlighting their technological leadership and competitive advantages.

Wang Tianyuan, CEO of ClickmabBy“Click.mAb: A Precise, Efficient, and User-Friendly AI Agent Platform Empowering ADC Drug Development”Focusing on three key aspects—antigen epitope selection, affinity levels, and immunogenicity—he provided an in-depth analysis of their impact on the efficacy of antibody-drug conjugates (ADCs). He further pointed out that AI-driven de novo antibody design enables precise, site-specific control over target epitopes, providing critical support for developing ADC antibodies with high-efficiency internalization activity. Additionally, this approach facilitates the diversification of antibody complementarity-determining regions (CDRs), thereby broadening the scope of patent protection. Finally, he demonstrated the potential of Clickmab’s Click.mAb. platform for antibody discovery and optimization through specific case studies.